DRUG — BRIGHT MINDS BIOSCIENCES INC

Ownership history in PERCEPTIVE ADVISORS LLC  ·  5 quarters on record

This page tracks every 13F SEC filing in which PERCEPTIVE ADVISORS LLC reported a position in BRIGHT MINDS BIOSCIENCES INC (DRUG). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.79% (2025 Q3)
Avg. % of fund
0.56%
First filed
2024 Q4
Last filed
2025 Q4
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 449,290 — 0% 0.62% $35.1M $78.04
2025 Q3 ADDED 449,290 +28,600 +6.8% 0.79% $27.3M $60.66
2025 Q2 REDUCED 420,690 -23,959 -5.4% 0.41% $11.0M $26.11
2025 Q1 ADDED 444,649 +41,000 +10.2% 0.57% $16.0M $36.07
2024 Q4 INITIATED 403,649 — — 0.40% $14.5M $36.02
% of Fund (quarterly)    DRUG price (monthly, adj. close)

Other funds also holding DRUG

As of 2025 Q4 — sorted by position size

ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 4.48% Cormorant Asset Management, LP 3Y 7Y 3.82% Vivo Capital, LLC 3Y 7Y 2.53% MPM BioImpact LLC 3Y 2.06% SUPERSTRING CAPITAL MANAGEMENT LP 1.98% STEMPOINT CAPITAL LP 1.3% Sio Capital Management, LLC 3Y 7Y 1.01% Ikarian Capital, LLC 3Y 0.97% BRAIDWELL LP 3Y 0.81% PLATINUM INVESTMENT MANAGEMENT LTD 3Y 7Y 0.39%
← Back to PERCEPTIVE ADVISORS LLC Holdings